Part I: General Information Date Prepared: March 2015 Name: Shuji Ogino Office Address



Download 0.66 Mb.
Page5/7
Date conversion08.07.2018
Size0.66 Mb.
1   2   3   4   5   6   7

2012 Novel Integrative Science of Molecular Pathological Epidemiology (MPE) of Cancer / Invited Lecture


Online Webinar
2012 Molecular Pathological Epidemiology (MPE): Novel Integrative Science / Keynote Lecture

Chinese American Biomedical Association (CABA) Expert Forum and Regulatory Training Graduation, Boston, MA

2013 Molecular Pathological Epidemiology (MPE): Novel Integrative Science / Invited Lecture

RIKEN Quantitative Biology Center, Osaka, Japan


2013 Molecular Pathological Epidemiology (MPE): Novel Integrative Science / Invited Lecture

University of Tokyo Global COE Program Retreat, Oiso, Japan

2013 Molecular Pathological Epidemiology (MPE) of Cancer: Novel Integrative Science / Invited Lecture

National Cancer Center, Tokyo, Japan

2013 Molecular Pathological Epidemiology (MPE): Novel Integrative Science / Invited Lecture

University of Tokyo Institute of Medical Sciences, Tokyo, Japan

2013 Molecular Pathological Epidemiology (MPE) of Cancer: Novel Integrative Science / Invited Lecture

The Japanese Foundation of Cancer Research Institute, Tokyo, Japan


2013 Molecular Pathological Epidemiology (MPE): Integrative Interdisciplinary Science / Lecture

The First International Molecular Pathological Epidemiology (MPE) Meeting, Boston, MA


2013 Molecular Pathological Epidemiology (MPE): Integrated Science of Host & Cancer Epigenetics / Invited Lecture

Genomics Research Meeting, Boston, MA


2013 Molecular Pathological Epidemiology: A Paradigm Shift to Address Heterogeneity of Disease Etiologies and Pathogenesis / Invited Lecture

Society for Epidemiologic Research (SER) Annual Meeting, Boston, MA


2013 Molecular Pathological Epidemiology (MPE): A Paradigm Shift to Address Heterogeneity of Disease Etiologies for Future Epidemiology / Keynote Lecture

German Society of Epidemiology (DGEpi) Annual Meeting, Leipzig, Germany


2013 Molecular Pathological Epidemiology (MPE): Overview of Its Paradigm and Wide Applicability Even without Tumor Tissue / Lecturer (and Session Chair)

12th International AACR Frontiers in Cancer Prevention Research Meeting, National Harbor, MD




2013 Tumor Biomarker Discovery for Aspirin Chemoprevention by Molecular Pathological Epidemiology (MPE) Approach / Lecturer

12th International AACR Frontiers in Cancer Prevention Research Meeting, National Harbor, MD


2013 Useful and Practical Biostatistics in Molecular Pathology / Lecturer

Association for Molecular Pathology (AMP) Annual Meeting, Phoenix, AZ


2014 Molecular Pathological Epidemiology (MPE): Ubiquitous Population Science / Lecturer and Discussion Leader

American Society of Preventive Oncology (ASPO) Meeting, Arlington, VA


2014 Power of Molecular Pathological Epidemiology (MPE) Approach to Discover Tumor Biomarkers for Precision Medicine / Plenary Lecturer

Drug Discovery & Therapy World Congress 2014, Boston, MA
2014 Molecular Pathological Epidemiology (MPE): Integrative Science to Advance Biomedical and Health Sciences / Plenary Lecturer

EITA Conference on New Media and Biomedical Research, Boston, MA
2014 Molecular Pathological Epidemiology (MPE): Meeting Aims, Opportunities, and Challenges

Opening Lecturer

The Second International Molecular Pathological Epidemiology (MPE) Meeting, Boston, MA
2014 The Second International Molecular Pathological Epidemiology (MPE) Meeting

Conference Chairperson


2016 (anticipated) Molecular Pathological Epidemiology (MPE): Integrative Analysis of Host (Immunity), Environment and Disease

Kumamoto University, Japan


2016 (anticipated; May 12-13) The Third International Molecular Pathological Epidemiology (MPE) Meeting

Conference Chairperson




Report of Clinical Activities and Innovations




Current Licensure and Certifications
1993- Medical License, Japan

2000- Diplomate in Anatomic Pathology and Clinical Pathology, American Board of Pathology

2001- Diplomate in Molecular Diagnostics, American Board of Clinical Chemistry

2001- Medical License, Commonwealth of Massachusetts

2003- Diplomate in Molecular Genetic Pathology, American Board of Pathology

Practice activities
2001-2004 General Surgical Pathology Department of Pathology, BWH 10 weeks per year

2004-2007 General Surgical Pathology Department of Pathology, BWH 8 weeks per year

2004-2007 Molecular diagnostics Department of Pathology, BWH 7 weeks per year

2007-2010 Molecular diagnostics Department of Pathology, BWH 15 weeks per year

2011-2012 Molecular diagnostics Department of Pathology, BWH 10 weeks per year

2012-2013 Molecular diagnostics Department of Pathology, BWH 8 weeks per year

2013-2014 Molecular diagnostics Department of Pathology, BWH 9 weeks per year

2014-2015 Molecular diagnostics Department of Pathology, BWH 10 weeks per year


Clinical Innovations


Bayesian analysis to predict genetic risks

I have developed a number of new methods of calculating risks. My methods enable us to calculate genetic risk when genetic testing results are available in proband or relatives, or test sensitivity varies among family members. My Bayesian analysis methods have been useful as cystic fibrosis (CF) and spinal muscular atrophy (SMA) carrier screening tests have become routine clinical practices.




Standardized nomenclature system in molecular pathology reporting for personalized precision medicine

As an expert in nomenclature of genes and gene variants and alterations, I have developed standardized molecular pathology reporting system. In Brigham and Women’s Hospital Center for Advanced Molecular Diagnostics (CAMD), I have been serving as a consultant on mutation nomenclature in Oncomap and OncoPanel tests. Standardized nomenclature system in pathology reports has become very important as genomic pathology tests are becoming routine clinical practices. I have played a major role in CAP (College of American Pathologists) Molecular Oncology Committee, to standardize molecular testing surveys. I have also played a major role in AMP (Association for Molecular Pathology) and frequently given workshops at AMP annual meetings.




Report of Technological and Other Scientific Innovations


Sensitive detection of tumor somatic mutation by Pyrosequencing

I have developed molecular assays to detect somatic mutations in the KRAS, BRAF and PIK3CA genes, which are commonly mutated in various tumors. The original paper which described KRAS Pyrosequencing (Ogino et al. J Mol Diagn 2005) has been cited 300 times. This method has been very popular and widely used around the world.




Measurement of genomic DNA methylation in LINE-1 repetitive elements in paraffin tumor tissue

I have developed an accurate and precise assay to measure LINE-1 methylation level by Pyrosequencing. This is a very simple method to estimate global DNA methylation level and easily applicable to archival paraffin tissue.




Establishment of "Molecular Pathological Epidemiology (MPE)", the emerging integrative field of science

Epidemiologic analyses between exposures and molecular changes in cancer had been performed under the umbrella of molecular epidemiology, which limited methodological and conceptual development associated with those analyses. In order to fully develop this potential groundbreaking area, I established the field of “Molecular Pathological Epidemiology (MPE)” (Ogino et al. J Natl Cancer Inst 2010; Ogino et al. Gut 2011; Ogino et al. Nat Rev Clin Oncol 2011; Ogino et al. Oncogene 2013). I have been advancing the MPE field as the first “Molecular Pathological Epidemiologist” (Ogino et al. Am J Epidemiol 2012). Through a unique combination of expertise in both pathology and epidemiology, my long-term goal is to transform pathology and epidemiology in an integrative way for both education and research, towards our goal of personalized precision medicine.



Establishment of novel concepts, the "Unique Tumor Principle" and the "Unique Disease Principle"
I established a new concept of "Unique Tumor Principle" (Ogino et al. Int J Epidemiol 2012; Ogino et al. Expert Rev Mol Diagn 2012), and more broadly, the "Unique Disease Principle" (Ogino et al. Mod Pathol 2013). These new concepts have substantial impacts on personalized precision medicine.


Proposal of "GWAS-MPE approach"

Genome-wide association studies (GWAS) have shown numerous risk loci for many different diseases, but GWAS has had little impact on clinical practice. A major issue in GWAS is that heterogeneous disease subtypes with differing risk associations are typically lumped together into one disease entity, which can dilute effect estimates for risk variants for specific subtypes. MPE design (GWAS-MPE approach; Ogino et al. Gut 2011) can be used as the next step of GWAS, to investigate causal mechanisms and refine effect estimates of risks for specific disease subtypes.




Creation of the "Colorectal Continuum" Paradigm / Theory / Concept

The Colorectal Continuum Theory (Yamauchi, Morikawa, et al. Gut 2012; Yamauchi, Lochhead, et al. Gut 2012) underscores the importance of interplay of gut microbiota, host factors (diet, immunity, inflammation, etc.), and carcinogenesis. Gastroenterology research and practice have been based on the long-standing dogma of proximal vs. distal colorectum. Thus, this new paradigm which I created has had substantial impacts on gastroenterology/pathology research and practice.




Establishment of “MPE Working Group”
To transform pathology and epidemiology by the integrative MPE field and concept, I recently created the “MPE Working Group”, to establish standardized methodologies in MPE research and contribute to personalized medicine. MPE Working Group currently consists of researchers in the MPE areas mainly based on Harvard School of Public Health, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute. As the group leader, I organize bimonthly MPE Working Group meeting to advance the MPE field.


Establishment of the “STROBE-MPE” Initiative

I initiated "STROBE-MPE" (Ogino et al. Int J Epidemiol, 2012; Ogino et al. Am J Epidemiol 2012), to establish international guidelines of MPE research, for personalized medicine and public health. STROBE stands for “STrengthening of the Reporting of OBservational Epidemiology” (von Elm et al. PLoS Med 2007), and is an international guideline for epidemiology research.



Report of Scholarship
[Current citation h-index = 66. h-index since 2010 = 59. Over 13,900 total citations with over 11,600 citations since 2010]
Peer-Reviewed Publications
Research Investigations [I am the first, last or co-last author in 116 (63%) of the 183 papers]
1. Kubo S, Ogino S, Fukushima T, Maruno M, Yoshimine T, Hasegawa H. Immunohistochemical detection of insulin-like growth factor II (IGF2) in choroid plexus papilloma: a possible marker for differential diagnosis. Clin Neuropathol 1999;18:74-79.
2. Ogino S, Cohen ML, Abdul-Karim FW. Atypical teratoid/rhabdoid tumor of the CNS: Cytopathology and immunohistochemistry of insulin-like growth factor-II, insulin-like growth factor receptor type 1, cathepsin D and Ki-67. Mod Pathol 1999;12:379-385.
3. Kubo S, Ogino S, Fukushima T, Olson PR, Kida M, Maruno M, Yoshimine T, Hayakawa T. Immunohistochemical study of insulin-like growth factor II (IGF2) and insulin-like growth factor binding protein-2 (IGFBP2) in choroid plexus papilloma. Neurol Res 1999;21:339-344.
4. Ogino S, Redline RW. Villous capillary lesions of the placenta: Distinctions between chorangioma, chorangiomatosis, and chorangiosis. Hum Pathol 2000;31:945-954.
5. Ogino S, Kubo S, Abdul-Karim FW, Cohen ML. Comparative immunohistochemical study of insulin-like growth factor (IGF)-II and IGF receptor type 1 in pediatric brain tumors. Pediatr Development Pathol 2001;4:23-31.
6. Ogino S, Leonard DGB, Rennert H, Gao S, Wilson RB. Heteroduplex formation in SMN gene dosage analysis. J Mol Diagn 2001;3:150-157.
7. Ogino S, Leonard DGB, Rennert H, Wilson RB. Spinal muscular atrophy genetic testing experience at an academic medical center. J Mol Diagn 2002;4:53-58.
8. Ogino S, Leonard DGB, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet 2002;110:301-307.
9. Ogino S, Wilson RB. Quantification of PCR bias caused by a single nucleotide polymorphism in SMN gene dosage analysis. J Mol Diagn 2002;4:185-190.
10. Ogino S, Wilson RB. Genotype and haplotype distributions of MTFHR 677C>T and 1298A>C single nucleotide polymorphisms: A meta-analysis. J Hum Genet 2003;48:1-7.
11. Ogino S, Gao S, Leonard DGB, Paessler M, Wilson RB. Inverse correlation between SMN1 and SMN2 copy numbers: Evidence for gene conversion from SMN2 to SMN1. Eur J Hum Genet 2003;11:275-277. (Addendum in 2003;11:723)
12. Xu R, Ogino S, Lip V, Fang H, Wu B. Comparison of PCR-RFLP assay with allele-specific PCR in genetic testing for spinal muscular atrophy. Genet Testing 2003;7:277-281.
13. Ogino S, Wilson RB, Grody WW. Bayesian risk assessment for autosomal recessive diseases: fetal echogenic bowel and one or no detectable CFTR mutation. J Med Genet 2004;41:e70.
14. Ogino S, Wilson RB, Gold B, Hawley P, Grody WW. Bayesian analysis for cystic fibrosis risks in prenatal and carrier screening. Genet Med 2004;6:439-449.
15. Khurana JS, Ogino S, Shen T, Parekh H, Scherbel U, DeLong W, Feldman MD, Zhang PJ, Wolfe H, Alman BA. Bone morphogenetic proteins are expressed by both bone-forming and non-bone-forming lesions. Arch Pathol Lab Med 2004;128:1267-1269.
16. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 genes: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet 2004;12:1015-1023.
17. Ogino S, Flodman P, Wilson RB, Gold B, Grody WW. Risk calculations for cystic fibrosis risks in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests. Genet Med 2005;7:317-327.
18. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-421.
19. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6656.
20. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006;19:59-68.
21. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-217.
22. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55:1000-1006.
23. Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:59-65.
24. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006;8:458-464.
25. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol 2006;19:1083-1090.
26. Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, Fuchs CS. Correlations of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 2006;30:1175-1183.
27. Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006;210:147-154.
28. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006;8:582-588.
29. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 2006;66:8625-8632.
30. Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is associated with microsatellite instability and CIMP. Mod Pathol 2007;20:15-22.
31. Ogino S, Wilson RB, Gold B, Flodman P. Bayesian risk assessment in genetic testing for autosomal dominant disorders with age-dependent penetrance. J Genet Counsel 2007;16:29-39.
32. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol 2007;38:585-592.
33. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol 2007;38:614-620.
34. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol 2007;38:842-849.
35. Meyerhardt JA, Clark JW, Supko J, Eder P, Ogino S, Stewart C, D’Amato F, Dancey J, Enzinger PC, Zhu A, Ryan DP, Earle C, Mayer R, Kinsella K, Fuchs CS. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemotherapy Pharmacol 2007;60:661-670.
36. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007;9:305-314.
37. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-2142. (I am the sole pathologist in this study.)
38. Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007;56:1564-1571.
39. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007;450:529-537.
40. Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M, Maher E, Ogino S, Fuchs CS, Li J, Hader C, Makrigiorgos GM. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn 2007;9:441-451.
41. Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 2007;7:72.
42. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, Ogino S. Correlation of -catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype in colorectal cancer. Neoplasia 2007;9:569-577.
43. Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Meyerhardt JA, Hunter DJ, Fuchs CS. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 2007;28:1985-1990.
44. Park DY, Sakamoto H, Kirley SD, Ogino S, Kawasaki T, Kwon E, Mino-Kenudson M, Lauwers GY, Chung DC, Rueda BR, Zukerberg LR. The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer. Am J Pathol 2007;171:1509-1519.
45. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, Ogino S. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype and p53. Neoplasia 2007;9:1091-1098.
46. Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M, Fuchs CS, Ogino S. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2008;21:150-158.
47. Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, Ogino S. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Mod Pathol 2008;21:245-255.
48. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S. Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008;8:33.
49. Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008;122:2767-2773.
50. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008;3:e2020.
51. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-541.
52. Firestein R, Bass AJ, Kim SY, Ian F. Dunn IF, Silver SJ, Guney I, Freed E, Ligon A, Vena N, Ogino S, Chheda M, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs C, Loda M, Shivdasani RA, Meyerson M, Hahn WC. CDK8 is a colorectal cancer oncogene that regulates -catenin. Nature 2008;455:547-551. PMCID: PMC2587138
53. Nosho K, Kawasaki T, Chan AT, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, Ogino S. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology 2008;53:588-598.
54. Schernhammer ES, Ogino S, Fuchs CS. Folate intake and risk of colon cancer in relation to p53 alteration. Gastroenterology 2008;135:770-780.
55. Schernhammer ES, Giovannucci EL, Fuchs CS, Ogino S. A prospective study of dietary folate and vitamin B and colon cancer according to MSI and KRAS mutational status. Cancer Epidemiol Biomarkers Prev 2008;17:2895-2898.
56. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, Hazra A, Chan AT, Dehari R, Giovannucci EL, Fuchs CS. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008;14:8221-8227.
57. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008;100:1734-1738.
58. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008;3:e3698.
59. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008;26:5713-5720.
60. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96.
61. Nosho K, Shima K, Kure S, Irahara N, Baba Y, Chen L, Kirkner GJ, Fuchs CS, Ogino S. JC virus T-antigen in colorectal cancer Is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia 2009;11:87-95.
62. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009;27:1477-1484.
63. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, Giovannucci EL, Fuchs CS. Colorectal cancer expression of peroxisome proliferator-activated receptor- (PPARG, PPARgamma) is associated with good prognosisis. Gastroenterology 2009;136:1242-1250.
64. Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 2009;11:418-425.
65. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS. A cohort study of p27 localization in colon cancer, body mass index and patient survival. Cancer Epidemiol Biomarkers Prev 2009;18:1849-1858.
66. Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L, Gokhale S, Hazra A, Spiegelman D, Giovannucci EL, Jaenisch R, Fuchs CS, Ogino S. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res 2009;15:3663-3671.
67. Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, Toyoda S, Chen L, Giovannucci EL, Meyerhardt JA, Fuchs CS. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 2009;15:4431-4438.
68. Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS, Ogino S. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2009;22:922-932.
69. Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 2009;15:4665-4673.
70. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Brit J Cancer 2009:101:465-472.
71. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-658. (I am the sole pathologist in this study)
72. Ogino S, Nosho K, Baba Y, Kure S, Shima K, Irahara N, Toyoda S, Chen L, Kirkner GJ, Wolpin BM, Chan AT, Giovannucci EL, Fuchs CS. A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am J Gastroenterol 2009;104:2047-56.
73. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol 2009;27:4591-4598.
74. Meyerhardt JA, Ogino S, Kirkner GJ, Chan AT, Wolpin B, Ng K, Nosho K, Shima K, Giovannucci EL, Loda M, Fuchs CS. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res 2009;15:5931-5936.
75. Ogino S, Nosho K, Shima K, Baba Y, Irahara N, Kirkner GJ, Hazra A, De Vivo I, Giovannucci EL, Meyerhardt JA, Fuchs CS. p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol Biomarkers Prev 2009;18:2513-2521.
76. Worthley DL, Le Leu RK, Whitehall V, Conlon M, Christophersen C, Belobrajdic D, Mallitt K, Hu Y, Irahara N, Ogino S, Leggett BA, Young GP. A human, double-blind, placebo-controlled, cross-over trial of prebiotic, probiotic and synbiotic supplementation: effects on luminal, inflammatory, epigenetic and epithelial biomarkers of colorectal cancer. Am J Clin Nutr 2009;90:578-586.
77. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009;15:6412-6420.
78. Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2765-2772.
79. Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 2009;137:1609-1620.
80. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson III AB, Goldberg RM, Bertagnolli MM, Fuchs CS: for the Cancer and Leukemia Group B, North Central Cancer Treatment Group, Canadian Cancer Society Research Institute, Southwest Oncology Group. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15:7322-7329.
81. Meyerhardt JA, Giovannucci EL, Ogino S, Kirkner GJ, Chan AT, Willett W, Fuchs CS. Physical activity and male colorectal cancer survival. Arch Int Med 2009;169:2102-2108.
82. Schernhammer ES, Giovannucci E, Kawasaki T, Rosner B, Fuchs CS, Ogino S. Dietary folate, alcohol, and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut 2010;59:794-799.
83. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL, Meyerhardt JA, Fuchs CS. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol 2010;105:420-433.
84. Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs CS, Ogino S. CDK8 expression in 470 colorectal cancers in relation to -catenin activation, other molecular alterations and patient survival. Int J Cancer 2010;126:2863-2873.
85. Irahara N, Nosho K, Baba Y, Shima K, Lindeman NI, Hazra A, Schernhammer ES, Hunter DJ, Fuchs CS, Ogino S. Precision of Pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa and peripheral blood cells. J Mol Diagn 2010;12:177-183.
86. Hazra A, Fuchs CS, Kawasaki T, Kirkner GJ, Hunter DJ, Ogino S. Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes Control 2010;21:331-45.
87. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010;19:157-163.
88. Worthley DL, Whitehall VLJ, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt K, Le Leu RK, Winter J, Hu Y, Ogino S, Young GP, Leggett BA. DNA methylation within the normal colorectal mucosa is associated with pathway specific predisposition to cancer. Oncogene 2010;29:1653-1662.
89. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 2010;176:2292–2301.
90. Baba Y, Nosho K, Shima K, Goessling W, Chan AT, Ng K, Chan JA, Giovannucci EL, Fuchs CS, Ogino S. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2010;19:822-831.
91. Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, Schernhammer ES, Hunter DJ, Giovannucci EL, Fuchs CS, Ogino S. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 2010;9:125.
92. Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Brit J Cancer 2010;103:1025-1033.
93. Baba Y, Nosho K, Shima K, Huttenhower C, Tanaka N, Hazra A, Giovannucci EL, Fuchs CS, Ogino S. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology 2010;139:1855-1864.
94. Tanaka N, Huttenhower C, Nosho K, Baba Y, Shima K, Quackenbush J, Haigis KM, Giovannucci E, Fuchs CS, Ogino S. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol 2010;177: 2731-2740.
95. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumor-infiltrating T-cell subsets, molecular changes in colorectal cancer and prognosis: cohort study and literature review. J Pathol 2010;222:350-366.
96. Chan AT, Baba Y, Shima K, Nosho K, Chung DC, Hung KE, Mahmood U, Madden K, Poss K, Ranieri A, Shue D, Kucherlapati R, Fuchs CS, Ogino S. Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia. Cancer Epidemiol Biomakers Prev: 2010;19:2777-2785.
97. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage and favorable outcome in 717 colorectal cancers. Cancer 2011;117:1399-1408.
98. Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. Int J Cancer 2011;128:1080-1094.
99. Worthley DL, Whitehall VLJ, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt K, Le Leu RK, Winter J, Hu Y, Ogino S, Young GP, Leggett BA. DNA methylation in the rectal mucosa is associated with epithelial proliferation and fecal short-chain fatty acid concentrations. Dig Dis Sci 2011;56:387-396.
100. Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs CS, Ogino S. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Cont 2011;22:301-309.
101. Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventative response to anti-inflammatory drugs. Gastroenterology 2011;140(3):799-808.e2.
102. Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, Ogino S. STAT3 expression, molecular features, inflammation patterns and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 2011;17:1452-1462.
103. Demicco EG, Farris, III, AB, Baba Y, Agbor-Etang B, Bergethon K, Mandal R, Daives D, Fukuoka J, Shimizu M, Dias-Santagata D, Ogino S, Iafrate AJ, Gaissert HA, Mino-Kenudson M. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs. cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 2011;24:1177-90.
104. Mino-Kenudson M, Fernández-del Castillo C, Baba Y, Valsangkar NP, Liss AS, Hsu M, Correa-Gallego C, Ingkakul T, Johnston RP, Turner BG, Androutsopoulos V, McGrath D, Sahani DV, Brugge WR, Ogino S, Pitman MB, Warshaw AL, Thayer SP. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histologic and precursor epithelial subtypes. Gut 2011;60:1712-1720.
105. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Association of CTNNB1 (β-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011;305:1685-1694.
106. Schernhammer ES, Giovannucci E, Baba Y, Fuchs CS, Ogino S. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PLoS ONE 2011;6:e21102.
107. Lee JE, Baba Y, Ng K, Giovannucci E, Fuchs C, Ogino S,* Chan AT.* Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res 2011;4:1808-1815. (* SO and ATC are co-last authors)
108. Shima K, Morikawa T, Yamauchi M, Kuchiba A, Imamura Y, Liao X, Meyerhardt JA, Fuchs CS, Ogino S. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS ONE 2011;6:e25062.
109. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Pugh T, Verhaak RG, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E, Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang DY, Signoretti S, Kaelin Jr WG, Spardy N, Hahn WC, Hoshida Y, Ogino S, DePinho RA, Chin L, Garraway LA, Fuchs CS, Baselga J, Tabernero J. Gabriel S, Lander ES, Getz G, Meyerson M. Genomic Sequencing of Colorectal Adenocarcinomas Identifies a Recurrent VTI1A-TCF7L2 Fusion. Nat Genet 2011;43:964-968.
110. Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson III AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 2011;103:1540-1551.
111. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-298.
112. Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS, Ogino S. Tumor TP53 expression status, body mass index, and prognosis in colorectal cancer. Int J Cancer 2012;131:1169-78.
113. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-854.
114. Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 2012;19:1944-1953.
115. Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the Nurses’ Health Study. J Natl Cancer Inst 2012;104:415-420.
116. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson III AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
117. Morikawa T, Shima K, Kuchiba A, Yamauchi M, Tanaka N, Imamura Y, Liao X, Qian ZR, Brahmandam M, Longtine JA, Lindeman NI, Fuchs CS, Ogino S. No evidence for interference of H&E staining in DNA testing: Utility of DNA extraction from H&E-stained archival tissue sections. Am J Clin Pathol 2012;138:122-129.
118. Habibollahi P, Figueiredo J, Heidari P, Dulak AM, Imamura Y, Bass AJ, Ogino S, Chan AT, Mahmood U. Optical imaging with a cathepsin B activated probe for the enhanced detection of esophageal adenocarcinoma by dual channel fluorescent upper GI endoscopy. Theranostics 2012;2:227-234.
119. Khalili H, Huang ES, Ogino S, Fuchs CS, Chan AT. A prospective study of bisphosphonate use and risk of colorectal cancer. J Clin Oncol 2012;30:3229-3233.
120. Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, Hornick JL, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, Schrag D, Fuchs CS, Ogino S. Predictors of lymph node count in colorectal cancer resections: Data from US nationwide prospective cohort studies. Arch Surg 2012;147:715-723. (Current journal name: JAMA Surgery)
121. Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res 2012;72:1547-1556.

122. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S. Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review. Clin Cancer Res 2012;18:2257-2268.



123. Lin JH, Morikawa T, Chan AT, Kuchiba A, Shima K, Nosho K, Kirkner G, Zhang SM, Manson JA, Giovannucci E, Fuchs CS, Ogino S. Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res 2012;72:3020-3028.


124. Phipps AI, Newcomb PA, Garcia-Albeniz X, Hutter CM, White E, Fuchs CS, Hazra A, Ogino S, Nan H, Ma J, Campbell PT, Figueiredo JC, Peters U, Chan AT. Association between colorectal cancer susceptibility loci and survival time following diagnosis with colorectal cancer. Gastroenterology 2012;143:51-54.e4.
125. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Nature 2012;487:500-504.
126. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF-wild-type colorectal cancers. Clin Cancer Res 2012;18:4753-4763.
127. Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, Fuchs CS, Ogino S. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer 2012;48:3405-3413.
128. Dulak AM, Schumacher S, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos A, Saksena G, Baca S, Baselga J, Tabernero J, Barretina J, Enzinger P, Corso G, Roviello F, Lin L, Bandla S, Luketich J, Pennathur A, Meyerson M, Ogino S, Shivdasani RA, Beer DG, Godfrey TE, Beroukhim R, Bass AJ. Gastrointestinal adenocarcinomas of the esophagus, stomach and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72:4383-4393.
129. Waldron L*, Ogino S*, Hoshida Y, Shima K, McCart Reed AE, Simpson PT, Baba Y, Nosho K, Segata N, Vargas AC, Cummings M, Lakhani SR, Kirkner GJ, Giovannucci E, Quackenbush J, Golub TR, Fuchs CS, Parmigiani G, Huttenhower C. Expression profiling of archival tissues for long-term health studies. Clin Cancer Res 2012;18:6136-6146. (* Co-first authors)
130. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-1606.
131. Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, Buring JE, Sesso HD, Lee IM, Rifai N, Pollak MN, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM. A prospective study of plasma adiponectin and pancreatic cancer risk in 5 U.S. cohorts. J Natl Cancer Inst 2013;105:95-103.
132. Ogino S, Nishihara R, Lochhead P, Imamura Y, Kuchiba A, Morikawa T, Yamauchi M, Liao X, Qian ZR, Sun R, Sato K, Kirkner GJ, Wang M, Spiegelman D, Meyerhardt JA, Schernhammer ES, Chan AT, Giovannucci E, Fuchs CS. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst 2013;105:130-140.
133. Nishihara R, Morikawa T, Kuchiba A, Lochhead P, Yamauchi M, Liao X, Imamura Y, Nosho K, Shima K, Kawachi I, Qian ZR, Fuchs CS, Chan AT, Giovannucci E, Ogino S. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol 2013;178:84-100.
134. Garcia-Albeniz X, Nan H, Valeri L, Morikawa T, Kuchiba A, Phipps AI, Hutter CM, Peters U, Newcomb PA, Fuchs CS, Giovannucci EL, Ogino S*, Chan AT*. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis 2013;34:292-298. (* Co-last authors)
135. Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, Kuo CJ, Camargo FD. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013;493:106-110.
136. Morikawa T, Kuchiba A, Lochhead P, Nishihara R, Yamauchi M, Imamura Y, Liao X, Qian ZR, Ng K, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S. Prospective analysis of body mass index, physical activity and colorectal cancer risk associated with β-catenin (CTNNB1) status. Cancer Res 2013;73:1600-1610.
137. Zhang X, Giovannucci EL, Wu K, Gao X, Hu F, Ogino S, Schernhammer ES, Fuchs CS, Redline S, Willett WC, Ma J. Associations of self-reported sleep duration and snoring with colorectal cancer risk in men and women. Sleep 2013;36:681-688.
138. Phipps AI, Chan AT, Ogino S. Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer 2013;119:3140-3147.
139. Bao Y, Giovannucci E, Kraft P, Qian ZR, Wu C, Ogino S, Gaziano JM, Stampfer MJ, Ma J, Buring JE, Sesso H, Lee IM, Rifai N, Pollak MN, Jiao L, Lessin LS, Cochrane BB, Manson JE, Fuchs CS, Wolpin BM. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of 5 U.S. cohorts. Cancer Epidemiol Biomarkers Prev 2013;22:855-861.
140. Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Brit J Cancer 2013;108:1891-1898.
141. Yamauchi M, Lochhead P, Imamura Y, Kuchiba A, Liao X, Qian ZR, Nishihara R, Morikawa T, Shima K, Wu K, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT, Ogino S. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013;22:1142-1152.
142. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC, Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R, Pennathur A, Ogino S, Luketich JD, Golub TR, Gabriel SB, Lander ES, Beer DG, Godfrey TE, Getz G, Bass AJ.  Exome and whole genome sequencing of esophageal adenocarcinoma identified recurrent driver events and mutational complexity. Nat Genet 2013;45:478-486.
143. Qian ZR, Ter-Minassian M, Chan JA, Imamura Y, Hooshmand SM, Kuchiba A, Morikawa T, Brais LK, Daskalova A, Heafield R, Lin X, Christiani DC, Fuchs CS, Ogino S, Kulke MH. Prognostic significances of MTOR pathway components expression in neuroendocrine tumors. J Clin Oncol 2013;31:3418-3425.
144. Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, Cochrane BB, Pollak MN, Manson JE, Giovannucci EL, Fuchs CS. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 2013;105:1027-1035.
145. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use and colorectal cancer incidence risk according to BRAF mutation status. JAMA 2013;309:2563-2571.
146. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S*, Chan AT*. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-1105. (* Co-last authors)

147. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013;105:1151-1156.


148. Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci E, Chan AT. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: A prospective study. Cancer Prev Res 2013;6:875-885.
149. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Rubinson DA, Stampfer MJ, Giovannucci EL, Fuchs CS, Wolpin BM. Prediagnostic body-mass index and pancreatic cancer survival. J Clin Oncol 2013;31:4229-4234.
150. Masuda A, Arisaka Y, Hara S, Matsumoto I, Takenaka M, Sakai A, Shiomi H, Matsuki N, Sugimoto M, Fujita T, Hayakumo T, Ku Y, Ogino S, Azuma T, Kutsumi H. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 2013;13:583-588.
151. Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N, Hooshmand SM, Brais LK, Lawrence MS, Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C, Grimsby J, Green L, Lennon N, Meyer T, Caplin M, Chung DC, Beutler AS, Ogino S, Thirlwell C, Shivdasani R, Asa SL, Harris CR, Getz G, Kulke M, Meyerson M. Somatic mutation of CDKN1B in small intestinal neuroendocrine tumors. Nat Genet 2013;45:1483-1486.
152. Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson III AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, for the Alliance for Clinical Trials in Oncology. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 2013;105:1789-1798.
153. Nan H, Morikawa T, Suuriniemi M, Yu Imamura Y, Werner L, Kuchiba A, Yamauchi M, Hunter DJ, Kraft P, Giovannucci EL, Fuchs CS, Ogino S, Freedman ML, Chan AT. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst 2013;105:1852-1861.
154. Nimptsch K, Malik VS, Fung TT, Pischon T, Hu FB, Willett WC, Fuchs CS, Ogino S, Chan AT, Giovannucci E, Wu K. Dietary patterns during high school and risk of colorectal adenoma in a cohort of middle-aged women. Int J Cancer 2014;134:2458-2467.
155. Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer 2014;13:135.
156. Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, Sougnez C, Voet D, Tabernero J, Jimenez J, Baselga J, Gabriel SB, Lander ES, Getz G, Eck MJ, Park WY, Meyerson M. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer 2014;13:141.
157. Lezcano C, Lee CW, Larson AR, Menzies AM, Kefford RF, Thompson JF, Mihm MC Jr, Ogino S, Long GV, Scolyer RA, Murphy GF. Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Mod Pathol 2014;27:1193-1202.
158. Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014;4:452-465.
159. Mehta RS, Song M, Bezawada N, Wu K, Garcia-Albeniz X, Morikawa T, Fuchs CS, Ogino S, Giovannucci EL, Chan AT. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst 2014;106:dju016.
160. Song M, Chan AT, Fuchs CS, Ogino S, Hu FB, Mozaffarian D, Ma J, Willett WC, Giovannucci EL, Wu K. Dietary intake of fish, ω-3 and ω-6 fatty acids and risk of colorectal cancer: a prospective study in U.S. men and women. Int J Cancer 2014;135:2413-2423.
161. Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, Cho E, Giovannucci E, Fuchs CS*, Ogino S*, Markowitz SD*, Chan AT*. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 2014;6:233re2. (* Co-last authors)
162. Naito T, Nosho K, Ito M, Igarashi H, Mitsuhashi K, Yoshii S, Aoki H, Nomura M, Sukawa Y, Yamamoto E, Adachi Y, Takahashi H, Hosokawa M, Fujita M, Takenouchi T, Maruyama R, Suzuki H, Baba Y, Imai K, Yamamoto H, Ogino S, Shinomura Y. IGF2 DMR hypomethylation in relation to pathological and molecular features of serrated lesions. World J Gastroenterol 2014:20:10050-10061.
163. Bezawada N, Song M, Wu K, Mehta RS, Milne G, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. Urinary prostaglandin metabolites (PGE-M) are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev Res 2014;7:758-765.
164. Sulahian R, Casey F, Shen J, Qian ZR, Shin H, Ogino S, Weir B, Vazquez F, Liu XS, Hahn WC, Bass A, Chan V, Shivdasani R. GATA6 transcriptional regulation in gastric cancer. Oncogene 2014;33:5637-5648.
165. Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA. Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). PLoS ONE 2014;9:e99816.
166. Jung S, Qian ZR, Yamauchi M, Bertrand KA, Fitzgerald KC, Inamura K, Kim SA, Mima K, Sukawa Y, Zhang X, Wang M, Smith-Warner SA, Wu K, Fuchs CS, Chan AT, Giovannucci EL, Ng K, Cho E, Ogino S,* Nishihara R. Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression. Cancer Epidemiol Biomarkers Prev 2014;23:1628-1637. (* Co-last and co-corresponding author)
167. Inamura K, Yamauchi M, Nishihara R, Lochhead P, Qian ZR, Kuchiba A, Kim SA, Mima K, Sukawa Y, Jung S, Zhang X, Wu K, Cho E, Chan AT, Meyerhardt JA, Harris CC, Fuchs CS, Ogino S. Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst 2014;106:dju195.
168. Li T, Liao X, Lochhead P, Morikawa T, Yamauchi M, Nishihara R, Inamura K, Kim SA, Mima K, Sukawa Y, Kuchiba A, Imamura Y, Baba Y, Shima K, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S*, Qian ZR. SMO expression in colorectal cancer: associations with clinical, pathological and molecular features. Ann Surg Oncol 2014;21:4164-4173. (* Co-last author)
169. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BM. Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development. Nat Med 2014;20:1193-1198.
170. Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, Herndon J, Cohoon TJ, Fleming T, Tamayo P, Mesirov JP, Ogino S, Wong KK, Ellis MJ, Hahn WC, Barbie DA, Gillanders WE. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest 2014;124:5411-5423.
171. Giannakis M, Hodis E, Mu J, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS, Qian ZR, Nishihara R, Van Allen EM, Hahn WC, Gabriel SB, Lander ES, Getz G, Ogino S, Fuchs CS, Garraway LA. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet 2014;46:1264-1266.
172. Nishihara R, Wang M, Qian ZR, Baba Y, Yamauchi M, Mima K, Sukawa Y, Kim SA, Inamura K, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Ogino S*, Schernhammer ES. Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. Am J Clin Nutr 2014;100:1479-1488. (* Co-last and corresponding author)
173. Fung TT, Kashambwa R, Sato K, Chiuve SE, Fuchs CS, Wu K, Giovannucci G, Ogino S, Hu FB, Meyerhardt JA. Post diagnosis diet quality and colorectal cancer survival in women. PLoS ONE 2014;9:e115377.
174. Ananthakrishnan AN, Du M, Berndt SI, Brenner H, Caan BJ, Casey G, Chang-Claude J, Duggan D, Fuchs CS, Gallinger S, Giovannucci EL, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hou L, Hsu L, Jenkins MA, Kraft P, Ma J, Nan H, Newcomb PA, Ogino S, Potter JD, Seminara D, Slattery ML, Thornquist M, White E, Wu K, Peters U, Chan AT. Red meat intake, NAT2, and risk of colorectal cancer: A pooled analysis of 11 studies. Cancer Epidemiol Biomarkers Prev: in press (published online).
175. Inamura K, Yamauchi M, Nishihara R, Kim SA, Mima K, Sukawa Y, Li T, Yasunari M, Zhang X, Wu K, Meyerhardt JA, Fuchs CS, Harris CC, Qian ZR, Ogino S. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol: in press (published online).
176. Yuan C, Rubinson DA, Qian ZR, Wu C, Kraft P, Bao Y, Ogino S, Ng K, Clancy TE, Swanson RS, Gorman MJ, Brais LK, Li T, Stampfer MJ, Hu FB, Giovannucci EL, Kulke MH, Fuchs CS, Wolpin BM. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol: in press (published online).
177. Song M, Gong J, Giovannucci EL, Berndt SI, Brenner H, Chang-Claude J, Curtis KR, Harrison TA, Hoffmeister M, Hsu L, Jiao S, Le Marchand L, Potter JD, Schoen RE, Seminara D, Slattery ML, White E, Wu K, Ogino S, Fuchs CS, Hunter DJ, Tworoger SS, Hu FB, Rimm E, Jensen M, Peters U, Chan AT. Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer: in press (published online).
178. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst 2015;107:dju345.
179. Jung S, Je Y, Giovannucci EL, Rosner B, Ogino S, Cho E. Derivation and validation of homocysteine score in US men and women. J Nutr: in press (published online).
180. Song M, Nishihara R, Wang M, Chan AT, Qian ZR, Inamura K, Zhang X, Ng K, Kim SA, Mima K, Sukawa Y, Nosho K, Fuchs CS, Giovannucci EL, Wu K, Ogino S. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut in press.
181. Song M, Nishihara R, Wu K, Qian ZR, Kim SA, Sukawa Y, Mima K, Inamura K, Masuda A, Yang J, Fuchs CS, Giovannucci EL, Ogino S,* Chan AT. Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability. J Natl Cancer Inst 2015 (in press). (* Co-last and co-corresponding author)
182. Hsu L, Jeon J, Brenner H, Gruber SB, Schoen RE, Berndt SI, Chan AT, Chang-Clude J, Du M, Gong J, Harrison TA, Hayes RB, Hoffmeister M, Hutter CM, Lin Y, Nishihara R, Ogino S, Prentice RL, Schumacher FR, Seminara D, Slattery ML, Thomas DC, Thornquist M, Newcomb PA, Potter JD, Zheng Y, White E, Peters U, on behalf of the Colorectal Transdisciplinary (CORECT) Study and Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). A model to determine colorectal cancer risk using common genetic susceptibility loci. Gastroenterology 2015 (in press).
183. Wang M, Kuchiba A, Ogino S. A meta-regression method for studying etiologic heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol 2015 (in press).

1   2   3   4   5   6   7


The database is protected by copyright ©dentisty.org 2016
send message

    Main page